SEC Form 4 · accession 0001485003-19-000010
Sesen Bio, Inc. · SESN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas R Cannell
Officer — President and CEO · Director
Period of report
Feb 21, 2019
Accepted (ET)
Feb 25, 2019 · 4:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001485003
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $0.8285 | Feb 21, 2019 | A | 1,000,000 | A | — | Feb 21, 2029 | Common Stock | 1,000,000 | 1,000,000 | D |
Explanation of responses
- F1On February 21, 2019, the reporting person was awarded options to purchase 1,000,000 shares of the common stock of Sesen Bio, Inc. (the "Company"), which options vest 6.25% every three months over four years provided the reporting person is employed by the Company at each such vesting date.